Impact on HbA1c and body weight of switching from other GLP‐1 receptor agonists to semaglutide: A model‐based approach
Open Access
- 25 July 2018
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (1), 43-51
- https://doi.org/10.1111/dom.13479
Abstract
Aims Semaglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue approved for the treatment of type 2 diabetes. The impact of switching treatment from another GLP‐1 receptor agonist (GLP‐1RA) to semaglutide was investigated by analyses of exposure‐response models. Methods HbA1c and body weight time‐course models were developed using up to 30 weeks of observations from 4 trials in the semaglutide phase 3 programme. Given the recommended dosing for each GLP‐1RA, pharmacokinetic profiles were simulated based on published population pharmacokinetic models and exposure was adjusted by the relative potencies to ensure that model predictions matched the effects observed in clinical trials. After 26 weeks of simulated treatment with liraglutide, dulaglutide or exenatide extended‐release, simulated semaglutide treatment was initiated one day after the last once‐daily liraglutide dose and one week after the last once‐weekly dulaglutide or exenatide extended‐release doses. Results The potency‐adjusted total effective GLP‐1RA concentration increased after switching from another GLP‐1RA to semaglutide and was associated with reductions ranging from ~0.3 to ~0.8 %‐points for HbA1c and from ~2 to ~4% for body weight with semaglutide 1.0 mg. Temporary slight deteriorations in HbA1c were observed after switching to semaglutide 0.25 mg from liraglutide 1.2/1.8 mg or dulaglutide 1.5 mg. Conclusions Exposure‐response modelling suggests that switching to semaglutide from liraglutide, dulaglutide or exenatide extended‐release results in further reductions in HbA1c and body weight. Initial slight deterioration in outcome values when switching to semaglutide 0.25 mg could be avoided by initiating semaglutide treatment at a higher dose.Keywords
Funding Information
- Novo Nordisk
This publication has 34 references indexed in Scilit:
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsInternational Journal of Obesity, 2013
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label studyThe Lancet, 2012
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- Long-Acting Glucagon-Like Peptide 1 Receptor AgonistsDiabetes Care, 2011
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple DosingClinical Pharmacokinetics, 2011
- Patient perspectives on once-weekly medications for diabetesDiabetes, Obesity and Metabolism, 2010
- The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studiesDiabetes, Obesity and Metabolism, 2009
- The Physiology of Glucagon-like Peptide 1Physiological Reviews, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy menDiabetologia, 2002